Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

Sam K. Bouchillon; Jonathan R. Iredell; Timothy Barkham; Kyungwon Lee; Michael J. Dowzicky

doi:10.1016/j.ijantimicag.2008.07.031

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

Sam K. Bouchillon, Jonathan R. Iredell, Timothy Barkham, Kyungwon Lee, Michael J. Dowzicky

Department of Laboratory Medicine

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC₉₀ values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

Original language	English
Pages (from-to)	130-136
Number of pages	7
Journal	International Journal of Antimicrobial Agents
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.ijantimicag.2008.07.031
Publication status	Published - 2009 Feb

Bibliographical note

Funding Information:
Funding : The study and preparation of this manuscript was funded by Wyeth Pharmaceuticals.

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijantimicag.2008.07.031

Fingerprint

Dive into the research topics of 'Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)'. Together they form a unique fingerprint.

Cite this

Bouchillon, S. K., Iredell, J. R., Barkham, T., Lee, K., & Dowzicky, M. J. (2009). Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). International Journal of Antimicrobial Agents, 33(2), 130-136. https://doi.org/10.1016/j.ijantimicag.2008.07.031

Bouchillon, Sam K. ; Iredell, Jonathan R. ; Barkham, Timothy et al. / Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). In: International Journal of Antimicrobial Agents. 2009 ; Vol. 33, No. 2. pp. 130-136.

@article{09202123588442d2b24f1fbdac8d1db6,

title = "Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)",

abstract = "As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.",

author = "Bouchillon, {Sam K.} and Iredell, {Jonathan R.} and Timothy Barkham and Kyungwon Lee and Dowzicky, {Michael J.}",

note = "Funding Information: Funding : The study and preparation of this manuscript was funded by Wyeth Pharmaceuticals. ",

year = "2009",

month = feb,

doi = "10.1016/j.ijantimicag.2008.07.031",

language = "English",

volume = "33",

pages = "130--136",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "2",

}

Bouchillon, SK, Iredell, JR, Barkham, T, Lee, K & Dowzicky, MJ 2009, 'Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)', International Journal of Antimicrobial Agents, vol. 33, no. 2, pp. 130-136. https://doi.org/10.1016/j.ijantimicag.2008.07.031

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). / Bouchillon, Sam K.; Iredell, Jonathan R.; Barkham, Timothy et al.
In: International Journal of Antimicrobial Agents, Vol. 33, No. 2, 02.2009, p. 130-136.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

AU - Bouchillon, Sam K.

AU - Iredell, Jonathan R.

AU - Barkham, Timothy

AU - Lee, Kyungwon

AU - Dowzicky, Michael J.

N1 - Funding Information: Funding : The study and preparation of this manuscript was funded by Wyeth Pharmaceuticals.

PY - 2009/2

Y1 - 2009/2

N2 - As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

AB - As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

UR - http://www.scopus.com/inward/record.url?scp=58149185269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149185269&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.07.031

DO - 10.1016/j.ijantimicag.2008.07.031

M3 - Article

C2 - 18995992

AN - SCOPUS:58149185269

SN - 0924-8579

VL - 33

SP - 130

EP - 136

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 2

ER -

Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). International Journal of Antimicrobial Agents. 2009 Feb;33(2):130-136. doi: 10.1016/j.ijantimicag.2008.07.031

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this